Protara workers

tenacious in our search for transformative therapies

TARA-002

TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for multiple oncologic indications and lymphatic malformations (LMs). We are evaluating TARA-002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and LMs in the U.S.

IV CHOLINE CHLORIDE
FOR IFALD​

An investigational phospholipid substrate replacement therapy for intestinal failure-associated liver disease (IFALD).

Scroll to Top